Cantor Fitzgerald analyst Eric Schmidt initiated coverage of Immunocore with an Overweight rating and no price target. Immunocore represents an exceedingly rare “all-in-one” Product, Pipeline, and Platform story and is a top pick, the analyst tells investors in a research note. The firm estimates KIMMTRAK’s value at $36/share and thinks KIMMTRAK is likely to work in refractory cutaneous melanoma, where a Phase 2/3 trial is ongoing.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMCR:
- Immunocore initiated with an Overweight at Cantor Fitzgerald
- Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
- Immunocore initiated with Outperform on TCR leadership at Baird
- Immunocore to present at upcoming investor conferences
- Immunocore initiated with an Outperform at Baird
